Phathom Pharmaceuticals

Youtube Subscribe

Open: 11.71 Close: 11.64 Change: -0.07

Are you looking for information about Phathom Pharmaceuticals? We programmed an AI to summarize it for you.

How much time have you spent trying to decide whether investing in Phathom Pharmaceuticals? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Phathom Pharmaceuticals are: …

Concept Map

Semantic Network

Stock Summary

Phathom Pharmaceuticals, Inc. focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB).

Today's Summary

Wall Street analysts think 43.51% is the mean of analysts price targets for Phathom Pharmaceuticals. Institutional owners may ignore recent US$66m market cap.

Today's News

Phathom Pharmaceuticals to participate in upcoming june 2023 investor conferences. Phathom pharmaceuticals to be reported to be $0.63 Billion by Yahoo Finance. Phat Pharmaceuticals is a biopharmaceutical company. Phathom Pharmaceuticals, Inc. (PHAT) Have the Potential to Rally 81.38% as Wall Street Analysts expect? Wall Street analysts think 43.51% is the mean of analysts price targets for Phathom. Institutional owners may ignore recent US$66m market cap. FDA issues no action notice for Phathom Pharmas Investigational Candidate, Shares Plunge. FDA notified Phathom Pharmaceuticals Inc (NASDAQ: PHAT) that no action would be taken on the companys new drug application (NDA) for vonoprazan, under review as a treatment for erosive esophagitis. Phathom Pharmaceuticals stock price per share is $11.70 today (as of Jun 5, 2023) Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims. Phathom Pharmaceuticals, Inc. faces an EPS projection of -$4.11 for the current year as it continues to traverse through the clinical-stage development process. Phathom Pharmaceuticals Inc. (PHAT) Shares Down Despite Recent Market Volatility newsheater 5/25/2023. Eagle-Tribune Phathom. Announces Proposed Public Offering of Common Stock.

Stock Profile

"Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey."

Keywords

Are looking for the most relevant information about Phathom Pharmaceuticals? Investor spend a lot of time searching for information to make investment decisions in Phathom Pharmaceuticals. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Phathom Pharmaceuticals are: Phathom, Pharmaceuticals, Inc, PHAT, company, Wall, Street, and the most common words in the summary are: phathom, pharmaceutical, inc, stock, news, share, market, . One of the sentences in the summary was: Wall Street analysts think 43.51% is the mean of analysts price targets for Phathom Pharmaceuticals. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #phathom #pharmaceutical #inc #stock #news #share #market.

Read more →

Youtube Subscribe

---